Transaction Structure
- Beta will hold a 49% stake in the JV, with IMGSA holding the remaining 51%
- Beta will infuse US$3 million in the JV over a period of 3 years
- Part of the consideration will be settled by issuing equity shares to IMGSA
- Beta will transfer formulation technology to the JV as part of the transaction
Plant Acquisition and Capabilities
The acquired oncology formulation plant has manufacturing capabilities in both injectable and oral solid dosage forms. The plant is among few oncology dedicated plants in Algeria and has been qualified by Algerian regulatory authority for supply in Algeria tenders.
Market Context and Strategy
The Algerian oncology market is valued at approximately US$1 billion and is growing rapidly. The market is primarily tender-driven, with the Algerian government providing consistent impetus for localization of pharmaceutical manufacturing. The JV will leverage IMGSA's distribution network to cater to North African markets including Tunisia and Mauritania.
Governance Structure
The JV's Board will comprise five directors, with three appointed by Beta and two by IMGSA. The CEO/MD of the JV will be appointed by Beta and will be responsible for day-to-day operations.
Background Relationship
Beta has had a long-standing relationship with IMGSA over the last 4 years, during which Beta has supplied semi-finished and finished formulations to IMGSA and assisted in product registrations for the Algeria market. These product registrations will be transferred to the JV as part of the transaction.
Management Commentary
Rahul Batra, MD of Beta Drugs Limited, stated: "Our relationship with IMGSA has grown steadily over many years, and this joint venture marks a natural next step for us to deepen our relationship and commitment to the Algerian market."
Mr. Toufik Haouam, MD of IMGSA Groupe SPA, stated: "Beta has been a trusted partner for many years. This equity partnership strengthens our oncology capabilities and supports our commitment to local manufacturing."
Regulatory Status
The transaction is subject to customary conditions and regulatory approvals, as applicable.